Clinical trials: Macular Degeneration Choroidal Neovascularization
Age-related Macular Degeneration
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
- Trial name
- NCT02214628
- Testing
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Where
- 13 sites in United States
- Volunteers
- 101 people
- Sponsor
- Ophthotech Corporation
Macular Degeneration
A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
A study to evaluate pazopanib tablets in male and female adults of non-child bearing potential with subfoveal CNV due to neovascular AMD. The goal is to assess safety and how well the subjects tolerate the drug.
- Trial name
- NCT01154062
- Testing
- Pazopanib
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Macular Degeneration
Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5. Cand5, a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF.
- Trial name
- NCT00259753
- Testing
- Bevasiranib
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- OPKO Health, Inc.
Neovascular Age Related Macular Degeneration
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A study to use in home technology to reduce the burden of in office visits and injections.
- Trial name
- Liberty (NCT01863199)
- Testing
- Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Retinal Consultants of Arizona
Exudative Macular Degeneration
Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment
We propose to undertake a retrospective review of approximately 200 patients with a diagnosis of exudative macular degeneration treated with triple combination therapy (Bevacizumab, Dexamethasone and Photo-dynamic therapy) during…
- Trial name
- NCT02287298
- Testing
- TRIPLE COMBINATION THERAPY
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- The Retina Center of St. Louis County, PC
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV).
- Trial name
- POYANG (NCT06176352)
- Testing
- Faricimab, Ranibizumab
- Where
- 63 sites in Australia, China and 9 more
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Diabetic Proliferative Retinopathy, Vascular Vein Oclussion
Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment
Purpose: Determine the short-term safety of intravitreal bevacizumab by multifocal electroretinography (mf-ERG). Methods: 120 eyes with choroidal neovascularization, proliferative diabetic retinopathy and retinal vein occlusion…
- Conditions
- Diabetic Proliferative Retinopathy, Vascular Vein Oclussion, Choroidal Neovascularization
- Trial name
- NCT00417833
- Testing
- Intravitreal Bevacizumab
- Sponsor
- Asociación para Evitar la Ceguera en México
Vein Occlusion, Macular Degeneration Choroidal Neovascularization
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
The goal of this clinical trial is to learn how various topical drops (bromfenac, loteprednol, and artificial tears) fare in alleviating post-intravitreal injection pain.
- Conditions
- Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
- Trial name
- NCT07090044
- Testing
- Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Retina Research Institute, LLC
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Neovascular Age-related Macular Degeneration
Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration…
- Trial name
- IMAGINE (NCT04774926)
- Testing
- Brolucizumab
- Where
- 20 sites in Italy
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Pigment Epithelial Detachment
iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)
LT1009-Oph-002 is a Phase 1b study designed to evaluate the safety and potential efficacy of iSONEP following one, two or three injections of iSONEP, as needed, for the treatment of Pigment Epithelial Detachment (PED) secondary…
- Trial name
- PED (NCT01334255)
- Testing
- iSONEP (sonepcizumab/LT1009)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Lpath, Inc.
Age-Related Macular Degeneration, Choroidal Neovascularization
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
The primary purpose of this study is to assess the safety \& tolerability of an investigational drug 20089 TA (6.9 mg or 13.8 mg) when used adjunctively with Lucentis 0.5 mg in subjects with sub-foveal neovascular AMD.
- Trial name
- 20089/Combo (NCT01175395)
- Testing
- IBI-20089/Lucentis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Illinois Chicago
Evaluate the Association Between Certain Environmental Exposures (e.g. Cigarette Smoking, Alcohol Drinking, Betel Nut Chewing…) and Head and Neck Cancers, Assess the Effect of Genetic Factors, Including Both SNP and Copy Number Variation (CNV) Through Analysis of Both Main Effect and Gene-gene Interaction
International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study
Our overall objective is to understand the role of lifestyle factors, genetics and HPV infection in the development and prognosis of head and neck cancer particularly in Asia.
- Trial name
- InterCHANGE (NCT01972802)
- Where
- Taiwan
- Volunteers
- 900 people
- Sponsor
- National Taiwan University Hospital
Diabetic Retinopathy, Myopia
OCTA Metrics Repeatability and Reproducibility in Different Disorders
Retinal imaging is a corner stone in diagnosis of most retinal disorders. Standard imaging techniques e.g. fluorescein angiography and color fundus photography have a lot of limitations including limited resolution, invasive…
- Conditions
- Diabetic Retinopathy, Myopia, Choroidal Neovascularization, Healthy
- Trial name
- NCT04488887
- Testing
- Optical coherence tomography angiography
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tanta University
Polypoidal Choroidal Vasculopathy, Conbercept
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
1. To evaluate the effectiveness of Conbercept for PCV patients. 2. To describe the characteristics of PCV. 3. To describe the adverse events (AE) of Conbercept in the treatment of PCV. 4.
- Trial name
- NCT05229237
- Testing
- Conbercept
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Choroidal Neovascularisation
Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen
This study is designed to provide efficacy and safety data in patients with choroidal neovascularisation (CNV) secondary to myopia using an individualized as-needed (PRN) dosing schedule.
- Trial name
- REPAIR (NCT01037348)
- Testing
- ranibizumab 0.5mg
- Where
- 12 sites in United Kingdom
- Volunteers
- 65 people
- Sponsor
- Novartis
Myopic Choroidal Neovascularization
Ranibizumab for Myopic Neovascularization
The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
- Trial name
- NCT01246089
- Testing
- ranibizumab injection
- Where
- Brazil
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Choroidal Neo-Vascular Age-onset Macular Degeneration, Age-related Macular Degeneration
The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
The study will assess the safety and efficacy of Everolimus (RAD001) alone or in combination with Lucentis in patients with neo-vascular age related macular degeneration (AMD)
- Trial name
- NCT00857259
- Testing
- Everolimus, Ranibizumab
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Novartis Pharmaceuticals
Combretastatin A4 Phosphate, Age-related Macular Degeneration
Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration
The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration
- Conditions
- Combretastatin A4 Phosphate, Age-related Macular Degeneration, AMD, CNV
- Trial name
- NCT01570790
- Testing
- Combretastatin A-4 phosphate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Johns Hopkins University